Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.22.34: Legumain

This is an abbreviated version!
For detailed information about Legumain, go to the full flat file.

Word Map on EC 3.4.22.34

Reaction

hydrolysis of proteins and small molecule substrates at -Asn-/-Xaa- bonds =

Synonyms

AEP, Antigen Sj32, Antigen SM32, As-specific vacuolar cysteine proteinase, Asn-specific vacuolar cysteine proteinase, asparagine endopeptidase, asparaginly endopeptidase, asparaginyl endopepidase, Asparaginyl endopeptidase, asparaginyl endopeptidase legumain, asparaginyl endopeptidase,, asparaginyl proteinase, asparaginyl-specific cysteine endopeptidase, asparagyl-endopeptidase, aspartate-specific endopeptidase, AtLEGgamma, Bean endopeptidase, C197 legumain, c197 Sm32, cysteine protease 1, hemoglobinase, HlLgm, HlLgm2, IrAE, IrAE protein, isae1, isae2, LeG, LEG-1, Leg-2, Leg-4, Leg1, Leg2, Leg3, Leg4, Leg5, legumain, legumain-1, LGMN, lysosomal asparaginycysteine endopeptidase, lysosomal asparaginyl endopeptidase, lysosomal cysteine proteinase, More, N197 legumain, osteoclast inhibitory peptide 2, Ov-aep-1, Phaseolin, Proteinase B, PrVPE1, schistosome legumain, Sj32, Sm32, SmAE, SmAE protein, SPAE, TcLEG3, TcLEG6, TcLEG9, TvAE1, vacuolar processing enzyme, vacuolar processing enzyme 1a, vacuolar processing enzyme 1b, vacuolar processing enzyme 2, vacuolar processing enzyme 3, Vicilin peptidohydrolase, VPE, VPE1a, VPE1b, VPE2, VPE3

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.22 Cysteine endopeptidases
                3.4.22.34 Legumain

Inhibitors

Inhibitors on EC 3.4.22.34 - Legumain

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]cyclopropyl)carbamic acid
-
-
(1-[[(2S)-2-[[2-(2-amino-2-oxoethyl)-2-[[(2S,3S)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl]hydrazinyl]carbonyl]pyrrolidin-1-yl]carbonyl]cyclopropyl)carbamic acid
-
-
(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidine-1-carboxylic acid
-
-
(2S)-2-[[2-(2-amino-2-oxoethyl)-2-[[(2S,3S)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl]hydrazinyl]carbonyl]pyrrolidine-1-carboxylic acid
-
-
(2S)-N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2-[[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl](methanesulfonyl)amino]butanamide
-
(3-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]phenyl)carbamic acid
-
-
(3S)-3-[(1-acetyl-L-prolyl)amino]-5-[(2,6-dimethylbenzoyl)oxy]-4-oxopentanoic acid
-
starting structure for development of activity-based probes for in vivo imaging
(4-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]benzyl)carbamic acid
-
-
1,10-phenanthroline
2,2-dimethyl-propionic acid 3-benzyloxycarbonylamino-4-carbamoyl-2-oxo-butyl ester
-
weak inhibition
2,6-dimethyl-benzoic acid 3-benzyloxycarbonylamino-4-carbamoyl-2-oxo-butyl ester
-
enters cells and causes complete, irreversible inhibition of the enzyme, inhibition of autocatalytic processing in vivo
2-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]piperidine-1-carboxylic acid
-
-
3-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]-3,4-dihydroisoquinoline-2(1H)-carboxylic acid
-
-
4-(2-aminoethyl) benzenesulfonyl fluoride
AEBSF, 45.8% inhibition at 5 mM
4-chloromercuribenzoate
-
-
4-[[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]carbonyl]-1,3-thiazolidine-3-carboxylic acid
-
-
Ac-Tyr-Val-Ala-Asp-chloromethylketone
the rate of inhibition by Asp-CMK is approximately 3times more rapid at pH 4.0 than at pH 5.5
acetyl-Glu-Ser-Glu-Asn-aldehyde
Acetyl-Tyr-Val-Ala-Asp-aldehyde
Ala-Ala-Asn-chloromethylketone
the rate of inhibition by Asn-CMK is approximately 1.3times more rapid at pH 5.5 than at pH 4.0
alpha-2-Macroglobulin
proteinase inhibitor, may be a candidate for the binding of legumain as it is an agent for the removal of endopeptidases from extracellular fluids
-
antipain
papain-like cysteine proteinase inhibitor, 28.77% inhibition at 0.1 mM concentration relative to control
asparaginyl endopeptidase inhibitor
-
i.e. AEPi or cysteine protease inhibitor
-
atorvastatin
-
-
benzoic acid 3-benzyloxycarbonylamino-4-carbamoyl-2-oxo-butyl ester
-
-
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-benzyloxymethylketone
-
moderate inhibition
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-bromoacetate
-
-
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-bromomethylketone
-
strong specific and irreversible inhibition
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-chloroacetate
-
-
benzyloxycarbonyl-L-Ala-L-Ala-azaAsn-chloromethylketone
Benzyloxycarbonyl-Phe-Ala-CHN2
-
-
Boc-azaAsn-CH=CH-COOEt
-
-
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Boc-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
Boc-Piz-Ala-Ala-azaAsn-CH=CH-COOBzl
Boc-Piz-Ala-Ala-azaAsn-CH=CH-COOEt
Boc-Piz-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
Ca2+
moderate inhibition
carbobenzyloxy-Ala-Ala-(aza-Asn)-epoxycarboxylate ethyl ester
caspase 1 inhibitor V
-
-
-
Cbz-Ala-Ala-azaAsn-CH=CH-COOEt
Cbz-Ala-Ile-azaAsn-CH=CH-COOEt
CBZ-Ala-Phe-azaAsn-CH=CH-CO-tetrahydroisoquinoline
-
-
CBZ-Ala-Phe-azaAsn-CH=CH-CONHCH2-furyl
-
-
Cbz-Ala-Val-azaAsn-CH=CH-CO-tetrahydroquinoline
Cbz-Ala-Val-azaAsn-CH=CH-CONHCH2-1-naphthyl
Cbz-Ala-Val-azaAsn-CH=CH-COOEt
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
Cbz-Piz-Ala-Ala-azaAsn-CH=CH-COOEt
Cbz-Piz-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
Cbz-Piz-Ala-azaAsn-CH=CH-CO-tetrahydroquinoline
Co2+
strong inhibition
cystatin
-
cystatin 3
strong inhibition
-
cystatin C
-
cystatin CPI-4
-
-
-
cystatin E
high affinity inhibitor of legumain
-
cystatin E/M
-
cystatin M
-
diisopropyl fluorophosphate
E-64
papain-like cysteine proteinase inhibitor, 7.51% inhibition at 0.3 mM concentration relative to control
egg white cystatin
concentration of 2 microM, 45.13% inhibition of recombinant protein activity
-
ethyl (2E)-4-[1-(2-amino-2-oxoethyl)-2-[[(2S)-1-(2-oxopropanoyl)pyrrolidin-2-yl]carbonyl]hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[(2E)-2-(acetylamino)but-2-enoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[(2R)-2-(acetylamino)-3-(4-hydroxy-3-nitrophenyl)propanoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[(2R)-2-(acetylamino)butanoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[(2R)-2-(acetylamino)pent-4-ynoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[2-(acetylamino)-2-methylpropanoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[2-(acetylamino)-3-methylbut-2-enoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[3-(acetylamino)benzoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-([(2S)-1-[4-(acetylamino)benzoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-[[(2S)-1-[[(2R)-1-acetylpiperidin-2-yl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-[[(2S)-1-[[(3S)-2-acetyl-1,2,3,4-tetrahydroisoquinolin-3-yl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-[[(2S)-1-[[(4S)-3-acetyl-1,3-thiazolidin-4-yl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2E)-4-[2-[[(2S)-1-[[1-(acetylamino)cyclopropyl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]-4-oxobut-2-enoate
-
-
ethyl (2S,3S)-3-[[1-(2-amino-2-oxoethyl)-2-[([2S)-1-(2-oxopropanoyl)pyrrolidin-2-yl]carbonyl]hydrazinyl]carbonyl]oxirane-2-carboxylate
-
-
ethyl (2S,3S)-3-[[2-([(2S)-1-[(2R)-2-(acetylamino)butanoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]carbonyl]oxirane-2-carboxylate
-
-
ethyl (2S,3S)-3-[[2-([(2S)-1-[(2R)-2-(acetylamino)pent-4-ynoyl]pyrrolidin-2-yl]carbonyl)-1-(2-amino-2-oxoethyl)hydrazinyl]carbonyl]oxirane-2-carboxylate
-
-
ethyl (2S,3S)-3-[[2-[[(2S)-1-acetylpyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]carbonyl]oxirane-2-carboxylate
-
starting structure for development of activity-based probes for in vivo imaging
ethyl (2S,3S)-3-[[2-[[(2S)-1-[[1-(acetylamino)cyclopropyl]carbonyl]pyrrolidin-2-yl]carbonyl]-1-(2-amino-2-oxoethyl)hydrazinyl]carbonyl]oxirane-2-carboxylate
-
-
FaCPI-1
-
strawberry cystatin, phytocystatin of Fragaria sp.
-
Fe2+
strong inhibition
High molecular weight kininogen
-
-
-
High-molecular mass kininogen
kinin-free, F1.2-free
-
Human cystatin C
-
human cystatin C mutant L9G
-
inhibitory potential similar to wild-type cystatin C
-
human cystatin C mutant N39K
-
reduced inhibitory effect compared to the wild-type cystatin C
-
human cystatin C mutant R8G
-
inhibitory potential similar to wild-type cystatin C
-
human cystatin C mutant V10G
-
inhibitory potential similar to wild-type cystatin C
-
human cystatin C mutant W106G
-
inhibitory potential similar to wild-type cystatin C
-
human cystatin E/M
-
type 2 cystatin
-
human cystatin F
-
type 2 cystatin
-
HvCPI-4
-
cystatin HvCPI-4 of Hordeum vulgare
-
HvCPI-4-deltaT143-Cterm
-
C-terminal extended part of cystatin HvCPI-4
-
HvCPI-4-deltaT151-Cterm
-
C-terminal extended part of cystatin HvCPI-4
-
HvCPI-4-Q86P
-
cystatin HvCPI-4 of Hordeum vulgare, mutant Q86P
-
iodoacetamide
iodoacetate
iodoacetic acid
0.1 mM, 82.4% remaining activity
L-3-carboxy-2,3-trans-epoxypropionyl-leucyl-amido(4-guanidino)butane
leupeptin
low molecular mass kininogen
-
-
Mg2+
moderate inhibition
Mn2+
moderate inhibition
Mu-Ala-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
Mu-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Mu-Ala-Ala-azaAsn-CH=CH-CONHCH2CH2CH2Ph
-
-
Mu-Ala-Ala-azaAsn-CH=CH-COOEt
Mu-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
Mu-Ala-Ala-azaAsn-EP(S,S)-CONHCH2-1-naphthyl
Mu-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
N-benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone
0.1 mM, 0.23% remaining activity
N-ethylmaleimide
N-Phenylmaleimide
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(2',4'-dichloro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(2'-chloro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(2,4-dichlorobenzene-1-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(3',4'-dichloro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(3',4'-difluoro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(3'-fluoro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-chloro[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-cyano[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-ethyl[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-methoxy[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-methyl[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4'-tert-butyl[1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4-bromobenzene-1-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4-chlorobenzene-1-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-(4-fluorobenzene-1-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-([1,1'-biphenyl]-4-sulfonyl)-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4'-(propan-2-yl)[1,1'-biphenyl]-4-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4'-[(propan-2-yl)oxy][1,1'-biphenyl]-4-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4-(2H-1,3-benzodioxol-5-yl)benzene-1-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-1-[4-(trifluoromethyl)benzene-1-sulfonyl]-L-prolinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[2'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(1-methyl-1H-indazol-5-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(1-methyl-1H-indazol-7-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(2-methyl-2H-indazol-5-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(2-methyl-2H-indazol-7-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(4-methylpyridin-3-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-(5-methylpyridin-3-yl)benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-[4-(trifluoromethyl)pyridin-3-yl]benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-2,2-dimethyl-3-[4-[5-(trifluoromethyl)pyridin-3-yl]benzene-1-sulfonyl]propanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(2',3'-difluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(2',4'-dichloro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(2',4'-difluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(3',5'-difluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(3'-fluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(4'-butyl[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(4'-chloro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(4'-fluoro[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-(4'-tert-butyl[1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-([1,1'-biphenyl]-4-sulfonyl)-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(1,3-benzothiazol-5-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(4-chloropyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(4-fluoropyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(4-tert-butylpyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(5-chloropyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-3-[4-(5-fluoropyridin-3-yl)benzene-1-sulfonyl]-2,2-dimethylpropanamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(ethanesulfonyl)-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[(3'-methoxy[1,1'-biphenyl]-4-yl)methyl]-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[(3'-propoxy[1,1'-biphenyl]-4-yl)methyl]-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[(3'-propoxy[1,1'-biphenyl]-4-yl)methyl]-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-(methanesulfonyl)-N2-[[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(2-methylpropane-1-sulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(ethanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-norvalinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2',3'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(propane-1-sulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(2'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3',4'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3',5'-difluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-chloro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-ethoxy[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(2-methylpropane-1-sulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-D-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-norvalinamide
-
N-[(1S)-3-amino-1-cyano-3-oxopropyl]-N2-[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]-N2-(methanesulfonyl)-L-alaninamide
-
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E)-4-oxo-4-phenylbut-2-enoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
N-[(2S)-1-{2-(2-amino-2-oxoethyl)-2-[(2E,4E)-hexa-2,4-dienoyl]hydrazinyl}-1-oxopropan-2-yl]-N2-[(benzyloxy)carbonyl]-L-alaninamide
N-[(benzyloxy)carbonyl]-L-alanyl-N-[(1S,3E)-1-(2-amino-2-oxoethyl)-5-[methyl(naphthalen-1-yl)amino]-2,5-dioxopent-3-en-1-yl]-L-alaninamide
i.e. aza-peptide Michael acceptor Aza-Asn-11a, inhibition of trans-processing and activation of the zymogen form of Schistosoma mansoni cathepsin B1 by prior incubation with the legumain-specific inhibitor Aza-Asn-11a, reaction in CPS buffer, pH 5.5 for 30 min
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1,3-dihydroisoindol-2-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(1-piperidylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2,3-dihydroindol-1-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(2-furyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-1H-quinolin-2-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3,4-dihydro-2H-quinolin-1-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(3-pyridyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-fluorobenzyl)carbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(4-phenyl-5,6-dihydro-2H-pyridin-1-ylcarbonyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methyl-1-naphthylmethylcarbamoyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenethylcarbamoyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-(methylphenylcarbamoyl)propenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-benzylmethylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-bis-(2-furylmethyl)carbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibenzylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-dibutylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-diethylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenethylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylbenzylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-phenylcarbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-carbamoylmethyl-N1-trans-3-(N-methyl-N-(1-(N-methyl-N-phenethylcarbamoyl)phenylethyl)carbamoylpropenoyl)hydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl(4-fluorobenzyl)carbamoylpropenoyl)-N1-carbamoylmethylhydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-1-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyl-2-naphthylmethylcarbamoylpropenoyl)-N1-carbamoylmethylhydrazine
N2-(N-benzyloxycarbonylalanylalanyl)-N1-trans-(3-benzyloxycarbonylpropenoyl)-N1-carbamoylmethylhydrazine
N2-(N-biotinylalanylalanyl)-N1-carbamoylmethyl-N1-trans-(3-ethoxycarbonylpropenoyl)hydrazine
Ni2+
strong inhibition
ovocystatin
-
p-chloromercuribenzene sulfonic acid
-
-
p-chloromercuribenzene-sulfonic acid
-
p-chloromercuribenzoate
-
-
pepstatin
concentration of 500 microM, 7.8% inhibition of recombinant protein activity
pepstatin A
phenylmethanesulfonyl fluoride
phenylmethylsulfonyl fluoride
Pip-Ala-Ala-azaAsn-CH=CH-CON(Bzl)-CH2-1-naphthyl
Pip-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
Pip-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Pip-Ala-Ala-azaAsn-CH=CH-CONHCH2CH2Ph
Pip-Ala-Ala-azaAsn-CH=CH-COOEt
Pip-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
Pip-Ala-Ala-azaAsn-EP(S,S)-CONHCH2-1-naphthyl
Pip-Ala-Ala-azaAsn-EP(S,S)-COOEt
Pip-Ala-azaAsn-CH=CH-CO-tetrahydroisoquinoline
Piz-Ala-Ala-azaAsn-CH=CH-CON(Bzl)2
Piz-Ala-Ala-azaAsn-CH=CH-CON(CH2-1-naphthyl)2
Piz-Ala-Ala-azaAsn-CH=CH-CON(CH3)CH2-1-naphthyl
Piz-Ala-Ala-azaAsn-CH=CH-COOBzl
Piz-Ala-Ala-azaAsn-CH=CH-COOEt
Piz-Ala-Ala-azaAsn-EP(S,S)-CON(Bzl)2
PMSF
serine peptidase inhibitor, 13.84% inhibition at 5 mM concentration relative to control
rat alpha1-macroglobulin
-
-
-
terramycin
-
tosyl-Phe-CH2Cl
-
-
trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane
trans-epoxysuccinyl-L-leucylamido-(4-guanidino) butane
E-64, concentration of 500 microM, 8.88% inhibition of recombinant protein activity
Z-Phe-Ala-CHN2
i.e. benzyloxycarbonyl-phenylalanyl-alanyl-diazomethane, 40.8% inhibition at 0.01 mM
Zn2+
moderate inhibition
[(2S)-1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-3-[4-hydroxy-3-[hydroxy(oxo)ammonio]phenyl]-1-oxopropan-2-yl]carbamate
-
-
[(2Z)-1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-1-oxobut-2-en-2-yl]carbamic acid
-
-
[1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamic acid
-
-
[1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-1-oxopent-4-yn-2-yl]carbamic acid
-
-
[1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-2-methyl-1-oxopropan-2-yl]carbamic acid
-
-
[1-[(2S)-2-([2-(2-amino-2-oxoethyl)-2-[(2E)-4-ethoxy-4-oxobut-2-enoyl]hydrazinyl]carbonyl)pyrrolidin-1-yl]-3-methyl-1-oxobut-2-en-2-yl]carbamic acid
-
-
[1-[(2S)-2-[[2-(2-amino-2-oxoethyl)-2-[[(2R,3R)-3-(ethoxycarbonyl)oxiran-2-yl]carbonyl]hydrazinyl]carbonyl]pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamic acid
-
-
additional information
-